Analysts' ratings for Capricor Therapeutics (NASDAQ:CAPR) over the last quarter vary from bullish to bearish, as provided by 12 analysts.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Analysts have set 12-month price targets for Capricor Therapeutics, revealing an average target of $31.67, a high estimate of $77.00, and a low estimate of $8.00. Observing a 33.46% increase, the current average has risen from the previous average price target of $23.73.

Exploring Analyst Ratings: An In-Depth Overview

The perception...